AstraZeneca rejects higher ‘final’ offer from Pfizer

AstraZeneca has rebuffed Pfizer’s increased offer of £55, saying it falls short of its value as an independent science-led company and brings “uncertainty” and risks for shareholders.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.